IP Library Granted Patent US 10,912,864
Granted Patent B2
US 10,912,864 · App. 16/428,505 · Granted Feb 9, 2021

Acellular soft tissue-derived matrices and methods for preparing same

Inventors: Benjamin Schilling (Jersey City, NJ); Andrew Madans (Jersey City, NJ); Abigail Phipps (East Brunswick, NJ); Thomas Tylutki (Rahway, NJ); Todd Nilsen (Howell, NJ); Yen-Chen Huang (East Brunswick, NJ); Evangelia Chnari (Scotch Plains, NJ)
Assignee: Musculoskeletal Transplant Foundation
A61L27/3886A61L27/3839A61L27/3895A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,912,864
App. No.
16/428,505
Granted
Feb 9, 2021
Kind
B2
Abstract

Compositions including a first soft tissue-derived matrix and a second soft tissue-derived matrix are provided, as well as methods of making such compositions. In some embodiments, the composition comprises delipidated, decellularized adipose tissue-derived matrix and delipidated, decellularized fascial tissue-derived matrix, which may be combined in various proportions. Such adipose-fascia matrix compositions provide improved volume retention when implanted into a patient. The composition may further include exogenous cells or other substances, and/or a carrier. The composition is suitable for use inplastic surgery procedures, including reconstructive or cosmetic surgery procedures, as well as procedures for wound treatment and tissue regeneration. The methods for making the compositions may involve separation of first and second soft tissues from one another, followed by performing one or more treatments on the separated soft tissues, then combining the treated soft tissues and, optionally, performing one or more additional treatments on the combined soft tissues.

Claims (23)

1. A composition, comprising an adipose component which is a delipidized, decellularized adipose tissue-derived matrix and a fascia component which is a decellularized fascial tissue-derived matrix, wherein the adipose component and fascia component are present in the composition in a predetermined ratio of adipose component:fascia component in a range of from about 99:1 to about 1:99 on a weight basis, whereby the composition provides greater volume retention at an implantation site after passage of a minimum period of time from implantation of the composition in a subject, wherein greater volume retention is greater compared to a composition having a predetermined ratio of 100:0.

2. The composition of claim 1 wherein the fascial tissue-derived matrix is also delipidized.

3. The composition of claim 1 , wherein the predetermined ratio is at least about 4:1.

4. The composition of claim 1 , wherein the predetermined ratio is at least about 1.1.

5. The composition of claim 1 , wherein the minimum time period after implantation is at least 3 weeks.

6. The composition of claim 1 , wherein the minimum time period after implantation is at least 12 weeks.

7. The composition of claim 1 , wherein the minimum time period after implantation is at least 6 months.

8. The composition of claim 1 , wherein said adipose component is essentially free of native nucleic acids, or said fascia component is essentially free of native nucleic acids, or both.

9. The composition of claim 1 , wherein one or both of the adipose and fascia components has been disinfected.

10. The composition of claim 1 , further having a water content of at least about 20%, by weight, based on the total weight of the composition, and wherein the composition is ready to use without requiring rehydration.

11. The composition of claim 1 , further having a water content of less than about 20%, by weight, based on the total weight of the composition, wherein the composition is in substantially dried particulate form.

12. The composition of claim 1 , further comprising exogenous tissuegenic cells.

13. The composition of claim 1 , further comprising at least one exogenous growth inductive substance.

14. The composition of claim 1 , further comprising a carrier.

15. The composition of claim 14 , wherein said carrier comprises at least one substance selected from the group consisting of: an isotonic solution, a sodium chloride solution, a lactated Ringer's solution, a phosphate-buffered saline solution, platelet rich plasma, hyaluronic acid and its derivatives, thrombin, fibrin, glycerin, collagen, lecithin, sugars, polysaccharides, and solutions thereof.

16. The composition of claim 15 , wherein the carrier comprises hyaluronic acid or its derivative.

17. The composition of claim 1 , further comprising a preservative.

18. The composition of claim 17 , wherein the preservative is a solution comprising: a salt, a buffer, a sugar, a vitamin, an alcohol, a hormone, an antioxidant, sodium benzoate, or combinations thereof.

19. The composition of claim 18 , wherein the preservative is a solution comprising hyaluronic acid or its derivative.

20. The composition of claim 1 , wherein in the composition has a final form selected from: particulate, pieces, chunks, a paste, a gel, a slurry, a suspension, a layer or coating deposited on another scaffold, and combinations thereof.

21. The composition of claim 1 , wherein the composition is provided in a pre-determined shape.

22. The composition of claim 21 , wherein the pre-determined shape is one or more shapes selected from: a block, a sheet, a polyhedron, a strip, a cylinder, a rod, a sphere, a cone, a pyramid, a film, a membrane, a block, a polyhedron, a strip, a cylinder, a rod, a sphere, a cone, a pyramid, and variations and combinations thereof.

23. An implant comprising the composition of claim 1 .

Assignments (2)
SECURITY INTEREST Recorded Jul 27, 2023
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 064401/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2020
From: PHIPPS, ABIGAIL; TYLUTKI, THOMAS; MADANS, ANDREW; NILSEN, TODD; CHNARI, EVANGELIA; HUANG, YEN-CHEN; SCHILLING, BENJAMIN
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 051990/0644 →
Continuity (4)
Continuation In Part 15217409 · Jul 22, 2016
Provisional Application 62347944 · Jun 9, 2016
Provisional Application 62196522 · Jul 24, 2015
Related Publication 20190298885A1 · Oct 3, 2019
Cited By (2)
US 12,447,180 US 12,629,453